Cathy Eng: Phase 3 Checkmate 8HW update from Dr. Lenz
Cathy Eng shared a post on X:
“Ph 3 Checkmate 8HW update from Dr. Lenz USC Norris Comprehensive Cancer Center regarding:
- Nivo/ipi versus Nivo versus Chemotherapy in MSI-H metastatic colorectal cancer (versus chemotherapy only at this time)
- Primary endpoint = PFS
- 2year PFS= 72% HR=0.21
- 46% crossover with PFS2 (83% versus 52%).”
Source: Cathy Eng/X
Cathy Eng is a Professor of Medicine, Hematology and Oncology, and is the Co-Director of GI Oncology and Co-Leader of the Gastrointestinal Cancer Research Program at the Vanderbilt-Ingram Cancer Center. She also holds the David H. Johnson Endowed Chair of Surgical and Medical Oncology.
Dr. Eng was previously a Professor of Medical Oncology at The University of Texas MD Anderson Cancer Center.Her primary clinical research interests include clinical trials involving innovative drugs for the treatment of colorectal, anal, and appendiceal cancers. She has a specific interest in young colorectal cancer patients as well as the role of immunotherapy in HPV-associated cancers.
Nationally, Dr. Eng has served in multiple leadership roles for ASCO, ASCO GI, ECOG, and the NCI Rectal/Anal Task Force. She has most recently been chosen to serve as the Vice-Chair for the SWOG GI Committee and the NCI GI Steering Committee.
